Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) continue to
place a substantial clinical and economic burden on healthcare systems despite prevention efforts. VABP is
associated with high mortality that can range from 20% to 50%. Though HABP is considered less severe than
VABP, serious complications occur in approximately half of these cases. Compounding the challenges of treating
HABP/VABP is the prevalence of infections caused by multidrug-resistant (MDR) bacteria, including ESBL-producing
and carbapenem-resistant Enterobacteriaceae and MDR P. aeruginosa. As the CDC and WHO have identified these
Gram-negative pathogens as serious healthcare threats, Infectious Disease specialists must continue to spread
awareness and implement strategies to minimize the burden of these infections that complement antimicrobial
Clinicians must be aware of the latest tools that can greatly enhance their ability to effectively identify and
manage HABP/VABP caused by MDR gram-negative pathogens. These tools include rapid diagnostics that can accurately
detect resistant pathogens as well as potent antimicrobial agents with novel modes of action that can overcome
resistance mechanisms. ID clinicians must have a thorough understanding of the properties of the newer therapeutic
options in order to optimally utilize therapeutics in a pathogen-specific manner when confronted with MDR pathogens.
This program is designed to build competence, confidence, and skills in the management of HABP/VABP while increasing
the understanding of how to utilize the latest tools as part of antimicrobial stewardship efforts and interprofessional healthcare team.
This continuing medical education activity is planned to meet the needs of healthcare providers in a variety of
practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term
care facilities, and academia. This activity would be especially beneficial for ID physicians and pharmacists who
are on the frontline of managing patients with serious bacterial infections.
At the conclusion of the educational activity, the learner should be able to:
- Discuss current epidemiological trends and resistance mechanisms of multidrug-resistant (MDR) Gram-negative bacteria
- Differentiate between hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial
pneumonia (VABP) when considering the burden, cause, and management approaches
- Identify how to optimally utilize the available tools aimed at improving clinical outcomes of patients with
HABP/VABP, including rapid diagnostic techniques and newer antimicrobial agents
- Evaluate the benefits in utilizing a pathogen-specific approach when managing patients with HABP/VABP caused
by MDR Gram-negative pathogens
Registration and Dinner: 6:00 – 6:30 PM|
Educational Program: 6:30 – 8:30 PM
|6:30 – 6:40 PM
||Welcome and Introduction |
Patient Case Introduction
Keith Kaye, MD
|6:40 – 7:00 PM
||Epidemiology and Mechanisms of MDR Gram-Negative Bacterial Infections|
Keith Kaye, MD
|7:00 – 7:20 PM
||Available Tools to Address Challenges of MDR |
George Karam, MD
|7:20 – 7:45 PM
||Strategies in Managing HABP/VABP: A Review of the Clinical Evidence |
Richard Wunderink, MD
|7:45 – 8:05 PM
||Maximizing Outcomes in the Management of HABP/VABP|
James Lewis, PharmD
|8:05 – 8:15 PM
||Patient Case Conclusions|
Led by James Lewis, PharmD
|8:15 – 8:30 PM
||Learning by Sharing: Q and A|
There is no fee to participate in this educational activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies
of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent
Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
Center designates this live activity for a maximum of 2.0 AMA PRA Category 1
should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts AMA PRA Category 1 Credit(s)™ for the PRA from organizations accredited by ACCME.
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit(s)™ as this is an ACCME
accredited program and its accreditation is recognized by Nurse Practitioner boards.
Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy
Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of
continuing pharmacy education credits for participating in this activity.
ACPE UAN: 0473-9999-19-005-L01-P Activity type:
For questions regarding accreditation, please contact
INSTRUCTION FOR CREDIT
To receive a Certificate of Credit, participants must register for the symposium, document attendance, and
complete and return the evaluation form.
Physicians: A Certificate of Credit will be emailed to you within 4 weeks after the symposium.
Pharmacists: Credit will be uploaded to CPE Monitor within 4 weeks after the symposium.
DISCLOSURE OF CONFLICTS OF INTEREST
Center for Independent Healthcare Education and Vemco MedEd require faculty, planners, and others who are in a
position to control the content of continuing education activities to disclose to the audience any real or
apparent conflict of interest related to the activity. All identified conflicts of interest are reviewed and
resolved to ensure fair balance, objectivity, and scientific rigor in all activities. The faculty is further
required to disclose discussion of off-label uses in their presentations.
AMERICANS WITH DISABILITIES ACT
Vemco MedEd and Center for Independent Healthcare Education fully comply with the Americans With Disabilities
Act. Please submit a written request at least 5 days prior to the meeting, and we will be glad to assist you
with any special needs required to make this program accessible to you. Please email your request
Jointly provided by
Center for Independent Healthcare Education and Vemco
Supported by an educational grant from Merck & Co., Inc.